ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VRTX Vertex Pharmaceuticals Inc

401.08
0.92 (0.23%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Vertex Pharmaceuticals Inc NASDAQ:VRTX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.92 0.23% 401.08 371.34 408.70 405.665 397.59 401.50 1,063,962 05:00:08

Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13

10/05/2021 2:01pm

Business Wire


Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Vertex Pharmaceuticals Charts.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 10:15 a.m. ET.

The audio portion of management's remarks will be available live through Vertex's website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

(VRTX-WEB)

Vertex Pharmaceuticals Incorporated Investors: Michael Partridge, 617-341-6108 Brenda Eustace, 617-341-6187 Manisha Pai, 617-429-6891

1 Year Vertex Pharmaceuticals Chart

1 Year Vertex Pharmaceuticals Chart

1 Month Vertex Pharmaceuticals Chart

1 Month Vertex Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock